Private Practice (Rheumatology), P,O, Box 30813, Santa Barbara, CA 93130, USA.
Arthritis Res Ther. 2010;12(1):R7. doi: 10.1186/ar2906. Epub 2010 Jan 11.
Nonsteroidal anti-inflammatory drugs are recommended for the relief of pain associated with hand osteoarthritis (OA) but do not alter the underlying structural changes that contribute to impaired physical function. The current analysis examined the relationship of pain relief with measures of function and global rating of disease in patients with hand OA.
This was a combined analysis of 2 prospective, randomized, double-blind, 8-week, multicenter, parallel-group studies comparing diclofenac sodium 1% gel with placebo gel (vehicle) in patients with radiographically confirmed mild to moderate hand OA. Patients (n = 783) aged > or = 40 years applied diclofenac sodium 1% gel (2 g) or vehicle to each hand 4 times daily for 8 weeks. Outcome measures included pain intensity assessed on a 100-mm Visual Analog Scale (VAS); the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) subscales for pain, stiffness, and physical function (100-mm VAS); and a global rating of disease (100-mm VAS). Change in VAS pain intensity from baseline to week 8 was categorized (<0%, 0%-<15%, 15%-<30%, 30%-<50%, 50%-<70%, and > or = 70%) without regard to treatment and compared in each category with the mean change from baseline in each AUSCAN subindex and the global rating of disease. Pearson correlations between changes in outcome measures from baseline to week 8 were calculated.
Changes in VAS pain intensity were accompanied by similar changes in AUSCAN scores and global rating of disease. Pearson correlations confirmed significant associations (P < 0.001) between change in VAS pain intensity and changes in AUSCAN pain (correlation coefficient [r] = 0.81), AUSCAN function (r = 0.75), AUSCAN stiffness (r = 0.66), and global rating of disease (r = 0.76).
Pain relief correlated with improvements in physical function, stiffness, and global rating of disease in patients with hand OA, irrespective of treatment. This suggests that pain or anticipation of pain inhibits physical function and influences patient perception of disease severity in hand OA. These results also suggest that any intervention to relieve the pain of hand OA may improve function and patient perception of disease severity, despite the absence of a disease-modifying mechanism of action.
Clinicaltrials.gov NCT00171652, NCT00171665.
非甾体类抗炎药被推荐用于缓解手骨关节炎(OA)相关疼痛,但不能改变导致身体功能受损的潜在结构变化。目前的分析检查了疼痛缓解与手部 OA 患者的功能和疾病总体评分测量值之间的关系。
这是两项前瞻性、随机、双盲、8 周、多中心、平行组研究的合并分析,比较了二氯芬酸钠 1%凝胶与安慰剂凝胶(载体)在影像学证实的轻度至中度手部 OA 患者中的疗效。年龄≥40 岁的患者(n=783)每天每只手应用二氯芬酸钠 1%凝胶(2 g)或载体 4 次,持续 8 周。评估的结局指标包括使用 100mm 视觉模拟量表(VAS)评估的疼痛强度;澳大利亚/加拿大骨关节炎手部指数(AUSCAN)的疼痛、僵硬和躯体功能子量表(100mm VAS);以及疾病的总体评分(100mm VAS)。从基线到第 8 周时 VAS 疼痛强度的变化(<0%、0%-<15%、15%-<30%、30%-<50%、50%-<70%和≥70%)不考虑治疗,并在每个类别中比较与基线相比,AUSCAN 每个子指数和疾病总体评分的平均变化。计算从基线到第 8 周时各结局指标变化之间的 Pearson 相关性。
VAS 疼痛强度的变化伴随着 AUSCAN 评分和疾病总体评分的相似变化。Pearson 相关性证实了显著的相关性(P<0.001),VAS 疼痛强度的变化与 AUSCAN 疼痛(相关系数[r] = 0.81)、AUSCAN 功能(r=0.75)、AUSCAN 僵硬(r=0.66)和疾病的总体评分(r=0.76)。
手部 OA 患者的疼痛缓解与躯体功能、僵硬和疾病总体评分的改善相关,而与治疗无关。这表明疼痛或对疼痛的预期会抑制躯体功能,并影响手部 OA 患者对疾病严重程度的感知。这些结果还表明,任何缓解手部 OA 疼痛的干预措施都可能改善功能和患者对疾病严重程度的感知,尽管没有改变疾病的作用机制。
Clinicaltrials.gov NCT00171652,NCT00171665。